Your browser doesn't support javascript.
loading
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
Abdel Rahman, Zaid H; Parrondo, Ricardo D; Heckman, Michael G; Wieczorek, Mikolaj; Miller, Kevin C; Alkhateeb, Hassan; Sproat, Lisa Z; Murthy, Hemant; Hogan, William J; Kharfan-Dabaja, Mohamed A; Peterson, Jess F; Baughn, Linda B; Hoppman, Nicole; Litzow, Mark R; Ketterling, Rhett P; Greipp, Patricia T; Foran, James M.
Afiliação
  • Abdel Rahman ZH; Division of Hematology and Medical Oncology, Mayo Clinic, USA.
  • Parrondo RD; Division of Hematology and Medical Oncology, Mayo Clinic, USA.
  • Heckman MG; Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
  • Wieczorek M; Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
  • Miller KC; Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Alkhateeb H; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Sproat LZ; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
  • Murthy H; Division of Hematology and Medical Oncology, Mayo Clinic, USA.
  • Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, USA.
  • Peterson JF; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • Baughn LB; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • Hoppman N; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • Litzow MR; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Ketterling RP; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • Greipp PT; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • Foran JM; Division of Hematology and Medical Oncology, Mayo Clinic, USA.
Br J Haematol ; 196(4): 963-968, 2022 02.
Article em En | MEDLINE | ID: mdl-34697797
We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr-ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr-ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease-positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo-haematopoietic cell transplantation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article